The U.S. Supreme Court’s unanimous June 15 ruling that huge cuts in 340B hospitals’ Medicare Part B drug reimbursement were unlawful “is a clear and much welcome victory for 340B hospitals,” 340B Report Publisher and CEO Ted Slafsky says in his latest column for medication management solutions company Omnicell.
Slafsky reached out to a half dozen attorneys who specialize in the 340B program for their thoughts about the court’s decision. He said those conversations yielded five key takeaways:
The U.S. Supreme Court’s unanimous June 15 ruling that huge cuts in 340B hospitals’ Medicare Part B drug reimbursement were unlawful “is a clear and much welcome victory for 340B hospitals,” 340B Report Publisher and CEO Ted Slafsky says in his latest column for medication management solutions company Omnicell.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
